Changes in dietary intake, plasma carotenoids and erythrocyte membrane fatty acids in breast cancer survivors after a lifestyle intervention: results from a single-arm trial.

BACKGROUND: The influence of nutrition on breast cancer prognosis is still inconclusive and therefore dietary interventions incorporating dietary biomarkers are needed to confirm compliance with dietary goals and clarify biological mechanisms. The present study assessed whether a lifestyle intervention in breast cancer survivors could affect dietary biomarkers of fruit and vegetables and fatty acids. METHODS: In this phase II single-arm trial, 37 overweight/obese early stage breast cancer patients completed a 12-week diet and exercise intervention. The intervention involved 1-h weekly diet sessions delivered by a dietician and 75-min bi-weekly physical activity sessions of moderate-to-high intensity led by trained monitors. Before and after the intervention, three 24-h dietary recalls were carried out to calculate nutrient intakes and, in addition, blood samples were taken to measure plasma carotenoids, vitamin E and retinol concentrations and erythrocyte membrane fatty acid (EFA) composition. Wilcoxon signed rank tests were used to assess changes in dietary and biomarkers measurements over the intervention period. RESULTS: After the intervention, there was a significant increase in the intake of dietary carotenoids (+15.1% compared to baseline) but not plasma carotenoids levels (+6.3%). Regarding the EFA levels, we observed a significant decrease in percentage of saturated fatty acids (-1.4%) and n-6 polyunsaturated fatty acids (-2.9%) and an increase in monounsaturated fatty acids (1.7%) and total and long-chain n-3 polyunsaturated fatty acids (by 13.1% and 13.7%, respectively). A favourable decrease in the ratio of long-chain n-6 to n-3 polyunsaturated fatty acids (-9.1%) was also observed. CONCLUSIONS: After a short-term diet and exercise intervention in overweight/obese breast cancer survivors, we observed significant changes in dietary nutrients and fatty acid biomarkers, suggesting positive dietary changes that could be relevant for breast cancer prognosis.

Identification of oestrogen, progesterone receptor and human epidermal growth factor receptor 2 expression in mediastinal metastases of breast cancer obtained by endobronchial ultrasound-guided transbronchial needle aspiration.

BACKGROUND: In breast cancer patients, the expression statuses of oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are crucial in the choice of treatment. Receptor expression in metastatic lesions can differ from the primary tumour. The aim of our study was to analyse the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to obtain samples allowing the identification of ER, PR and HER2 expression in patients with mediastinal metastases of breast cancer. PATIENTS AND METHODS: The clinical files of all patients with a final diagnosis of breast cancer mediastinal metastases diagnosed by EBUS-TBNA in our institution were retrospectively analysed. The ability of EBUS-TBNA to obtain samples that allowed hormone receptor and HER2 expression analysis was calculated. RESULTS: Twenty-four patients were included. ER, PR and HER2 assessments could be performed in 22, 20 and 22 patients, respectively. In 20 of the 24 patients it was possible to investigate all three types of receptor expression. In the remaining four cases, where ER, PR or HER2 expression tests could not be performed, it was due to a lack of tissue. In cases with adequate results for EBUS-TBNA and the primary tumour agreement was greater for ER (16/19) and HER2 (12/14) than PR (8/17). Based on receptor status, there was a change in the choice of treatment for five patients. CONCLUSION: In patients with breast cancer mediastinal metastases, ER, PR and HER2 expression can be assessed in samples obtained by EBUS-TBNA whenever a sufficient tissue sample is collected.

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer.

Platinum-based chemoradiotherapy (CRT) is a preferred standard of care for locally advanced head and neck cancer (HNC). However, survival benefit is small, with substantial toxicity and biomarkers of CRT resistance that could guide treatment selection and spare morbidity. Increased DNA repair in solid tumors may contribute to cancer cells' ability to survive in genotoxic stress environments afforded by therapy. We assessed mRNA expression levels of DNA repair-related genes BRCA1, RAP80, 53 binding protein 1 (53BP1), mediator of DNA damage checkpoint 1 (MDC1), and RNF8. We correlated our findings with response and overall survival in 72 head and neck patients treated with weekly carboplatin AUC 2 and radiotherapy. Complete response (CR) to CRT was 50 % in patients with low levels of 53BP1 compared to 6.3 % in patients with high levels (p = 0.0059). Of high BRCA1 mRNA expressors, 41.2 % had CR compared to 29.4 % of low expressors (p = 0.72). For a small group of patients with low 53BP1 and either high BRCA1 or RAP80, CRs were 66.7 and 71.4 %, respectively. A trend for better overall survival (OS) was found for patients with low 53BP1 (15 vs 8 m; p = 0.056). Our findings highlight the potential usefulness of 53BP1 mRNA as a predictive biomarker of response and overall survival in HNC patients treated with chemoradiotherapy. Those with high 53BP1 expression could derive only a meager benefit from treatment. Analysis of BRCA1 and RAP80 could further reinforce the predictive value of 53BP1. Although this was a retrospective study with small sample size, it could inform larger translational studies in HNC.

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study.

Chemotherapy remains as the only systemic treatment option available for basal-like breast cancer (BC) patients. Preclinical models and several phase II studies suggested that platinum salts are active drugs in this BC subtype though there is no randomized study supporting this hypothesis. This study investigates if the addition of carboplatin to a combination of an alkylating agent together with anthracyclines and taxanes is able to increase the efficacy in the neoadjuvant treatment context. Patients with operable breast cancer and immunophenotypically defined basal-like disease (ER-/PR-/HER2- and cytokeratin 5/6+ or EGFR+) were recruited. Patients were randomized to receive EC (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles) followed either by D (docetaxel 100 mg/m(2) × 4 cycles; EC-D) or DCb (docetaxel 75 mg/m(2) plus carboplatin AUC 6 × 4 cycles; EC-DCb). The primary end point was pathological complete response (pCR) in the breast following the Miller and Payne criteria. Ninety-four patients were randomized (46 EC-D, 48 EC-DCb). pCR rate in the breast was seen in 16 patients (35 %) with EC-D and 14 patients (30 %) with EC-DCb (P value = 0.61). pCR in the breast and axilla was seen in 30 % of patients in both arms. The overall clinical response rate was 70 % (95 % CI 56-83) in the EC-D arm and 77 % (95 % CI 65-87) in the EC-DCb arm. Grade 3/4 toxicity was similar in both arms. The addition of carboplatin to conventional chemotherapy with EC-D in basal-like breast cancer patients did not improve the efficacy probably because they had already received an alkylating agent. These findings should be taken into consideration when developing new agents for this disease.

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.

BACKGROUND: Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio-RT) with Pb may be an alternative for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in patients ineligible for high-dose cisplatin therapy. METHODS: Phase II, single-arm, multicentre study, with two-stage design, in patients ≥ 18 years with stage III-IVa-b LA-SCCHN unfit for platinum. Patients received Px + Pb (9 weeks) as IT followed by Bio-RT + Pb. Primary endpoint: overall response rate (ORR) after IT, defined as: more than 70% of patients achieving complete response (CR) or partial response (PR) to IT. Secondary end-points: progression-free survival, organ preservation rate, safety profile. RESULTS: Study ended prematurely (51 patients) due to slow recruitment. ORR: 66.7% (95% CI: 53.7-79.6), 8 (15.7%) CR and 26 (51.0%) PR. 39 patients (76%) completed radiotherapy (RT). Pb and/or Px-related adverse events (AEs) grade 3-4: 56.9% during IT and 63.4% during the concomitant phase, of which most common were skin toxicity (33.3%). Five deaths occurred during treatment, two of them (3.9%) were Pb and/or Px-related. CONCLUSIONS: Although underpowered, ORR was higher than the pre-specified boundary for considering the treatment active. Although Px + Pb as IT provides some benefit, the safety profile is worse than expected. To consider Pb + Px as IT as an alternative for platinum-unsuitable LA-SCCHN, further research/investigation would be needed.

Transoral robotic surgery for squamous cell carcinoma of the oropharynx in a primarily human papillomavirus-negative patient population.

PURPOSE: Transoral robotic surgery (TORS) is one of the main treatment options for non-locally advanced primary oropharyngeal cancer in the United States. However, its use is more limited in countries with a low incidence of human papillomavirus (HPV), such as Spain, in patients with advanced disease, and as salvage surgery. To shed light on the use and potential benefit of TORS in Spanish patients, we analyzed the functional and oncologic outcomes of TORS as both primary and salvage surgery in a primarily HPV-negative population which is representative of oropharyngeal squamous cell carcinoma (OPSCC) patients in Spain. MATERIAL AND METHODS: This is a retrospective analysis of prospectively collected data on OPSCC patients treated with TORS at our center between February 2017 and February 2019. RESULTS: Fifty-four OPSCC patients were included; 79.6% were males and 80.5% were HPV negative. Median age was 62 years. Primary surgery was performed on 73.7% (48.1% stage I-II; 51.9% stage III-IV) and salvage surgery on 25.9% of patients. Positive margin rates were 4.3% for T1-2 and 25.8% for T3-4. None of the stage I-II patients and 27.7% of stage III-IV patients required adjuvant treatment. Reconstructive surgery was performed in 19.2% of all patients. Normal swallowing was achieved in 92.7% of patients at 6 months after surgery. 1- and 2-year survival rates for all patients were 94.5% and 89%, respectively. The overall complication rate was 16.1%. Bleeding occurred in 11.5% of patients. Longer hospitalization time was associated with surgical complications (P = 0.03) and reconstructive surgery (P = 0.03) but not with salvage surgery. CONCLUSION: TORS is a safe and effective treatment for HPV-negative T1-2 OPSCC patients. The positive margin rate was worse in T3-4 patients, indicating the need for careful patient selection in this subgroup.

SEOM clinical guidelines for the treatment of head and neck cancer (2017).

Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category. In addition, there are new data about induction chemotherapy and the role of immunotherapy in HNC.

[Dose intensity received in breast cancer treatment with chemotherapy]. / Intensidad de dosis recibida en el tratamiento quimioterápico del cáncer de mama.

OBJECTIVE: To know relative dose intensity (RDI) in patients with breast cancer treated with chemotherapy. To determine the number of patients where RDI was < 85% of that programmed and the possible cause. METHOD: Retrospective study, four-month selection period. The following were recorded: age, body surface, protocol applied, intention of treatment, frequency of administration of cycles, number of cytostatic treatments previously received and filgrastim administration. The average RDI per patient and protocol was calculated. RESULTS: 110 patients were analysed, the average age of them being 55.4 years (interval: 31-84), average body surface 1.7 m2 (1.3-2.4). Overall average RDI was 91.0% (SD 10.7). 93.8% (10.6), 95.8% (6.3) and 81.9% (18.5) in neoadjuvant, adjuvant and palliative treatments, respectively. 20% of the patients did not reach a RDI = 85% of that programmed, average RDI 69.5% (3.29). A delay in the administration of chemotherapy equal or greater than seven days occurred in 45.4% of the cases, average RDI 80.7% (16.0). In the episodes where the dose was reduced because of toxicity, the RDI was 75.6% (13.6). Significant inverse ratios were obtained with age (p = 0.02) and line of treatment (p = 0.03) with the RDI. In 36.8%, dose reduction was caused by neutropenia; 52.9% received filgrastim. CONCLUSIONS: Most patients received the appropriate RDI. Age, previous treatments and intention of treatment were the variables with the greatest impact on the dose received. The delay in administering the cycle was the most frequent act minimising the toxicity and which least affected the treatment.

[Pneumonia in patients with chronic lymphocytic leukemia. Study of 30 episodes]. / Neumonías en pacientes con leucemia linfática crónica. Estudio de 30 episodios.

BACKGROUND: To analyse the etiology, diagnostic methods and response to therapy in 30 episodes of pneumonia diagnosed in 17 patients with chronic lymphocytic leukemia (CLL) between 1995 and 2000. PATIENTS AND METHOD: In each episode of pneumonia the following data were analysed: age, gender, treatment of CLL, antiinfectious prophylaxis, granulocytopenia, CD4/CD8 lymphocytes ratio, hipogammaglobulinemia, origin of pneumonia (nosocomial or community-acquired), localisation, respiratory insufficiency, need for mechanical ventilation, antimicrobial therapy and response. Diagnostic methods included blood and sputum cultures, fiberoptic bronchoscopy and search for antigens in urine (Legionella pneumophila serogroup 1, galactomannan, and Streptococcus pneumoniae). RESULTS: Median age of the series was 60 yr. (range 50-86) and 12 patients were male. Chlorambucil and prednisone were used in 13 cases and fludarabine in 8. Granulocytopenia was present in 14 episodes, hypogammaglobulinemia was seen in 22 and CD4/CD8 ratio was lower than 1 in 8 out of 14 evaluable cases. Etiology of pneumonia was established in 16 episodes (53%). Fiberoptic bronchoscopy was the most useful technique (83% of positive diagnoses) followed by blood cultures (38%). Two patients were diagnosed of aspergillosis at autopsy. Pneumococcus was the most frequent agent (5 cases) followed by Pseudomonas aeruginosa (4), Pneumocystis carinii (2) and Aspergillus fumigatus (2). One out of the two patients with P. carinii pneumonia had received fludarabin and the remaining was treated with prednisone for long time. Ten patients (30%) had died: P. aeruginosa (3 cases), P. carinii (2), A. fumigatus (2), Mycobacterium xenopi (1), and unknown microorganism (2). CONCLUSIONS: In this series of CLL patients the frequency of etiologic diagnosis of pneumonias was good. Pneumococcus was the most frequent microorganism. Pneumonias caused by opportunistic microorganisms were associated to the treatment with fludarabin or prednisone and were associated to a high mortality rate.

Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors.

Energy restriction from a low-calorie diet and increased energy expenditure induced by physical activity (PA) could promote weight loss/maintenance and be important determinants of breast cancer (BC) prognosis. The aim of this study was to assess participation and adherence of overweight and obese BC survivors to a lifestyle intervention and to demonstrate the capacity of this intervention to induce weight loss and nutritional changes. This single-arm pre-post study, which involved one-hourly weekly diet sessions delivered by a dietician and 75-min bi-weekly PA sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, quality of life (QoL) and cardiorespiratory fitness (CRF) were collected. A total of 112 BC survivors were invited to participate: 42 of them started the intervention and 37 completed it. Participants attended more than 90 % of the sessions offered and showed a significant weight loss of 5.6 ± 2.0 kg, as well as significant decreases in body mass index, fat mass and waist circumference. Significant decreases in total energy (-25 %), fat (-35 %), saturated fat (-37 %) and carbohydrate (-21 %) intakes were observed while QoL and CRF showed significant increases. This feasibility study demonstrated the success of a short-term diet and PA intervention to induce weight loss and promote healthful changes in BC survivors. Assessing the long-term effects of these changes, and in particular their possible impact of BC prognosis, and designing interventions reaching a wider number of BC survivors are still issues to be addressed.

SEOM clinical guidelines for the treatment of head and neck cancer (2017)

Head and neck cancer (HNC) is defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2013 publication, Spanish Society of Medical Oncology (SEOM) presents an update of HNC diagnosis and treatment guideline. The eighth edition of TNM classification, published in January 2017, introduces important changes for p16-positive oropharyngeal tumours, for lip and oral cavity cancer and for N3 category. In addition, there are new data about induction chemotherapy and the role of immunotherapy in HNC (AU)

No disponible

Una forma factible y precisa de ubicar las microcalcificaciones de mama: dando una oportunidad a la técnica SNOLL / A feasible and accurate way to locate breast microcalcifications: Giving Snoll a chance

Objetivos: Para valorar la viabilidad y precisión de la técnica de SNOLL en la localización de microcalcificaciones mamarias malignas planteamos un estudio prospectivo observacional multicéntrico. Evaluamos la aplicación de la técnica y la evolución de las pacientes en un periodo de 10 años. Materiales y métodos: Entre 2007 y 2010, se reclutaron 64 pacientes. Todas las pacientes habían sido diagnosticadas de neoplasia de mama por microcalcificaciones en mamografía y fueron tratadas con cirugía conservadora y biopsia de ganglio centinela. Las inyecciones de tecnecio-99m se realizaron de forma preoperatoria, con una o varias punciones (en lesiones > 3,5 cm), guiadas por mamografía o ecografía. En todos los casos se realizó una linfogammagrafía preoperatoria para valorar la migración del radiotrazador y una mamografía intraoperatoria para valorar la correcta extirpación de la lesión. Resultados: En las 64 pacientes se realizó la inyección de radiotrazador y la linfogammagrafía demostró la correcta migración del contraste al ganglio centinela, permitiendo la exéresis de la lesión mamaria y del ganglio centinela en el 100% de los casos. La mamografía intraoperatoria mostró la exéresis completa de la lesión en el 100% de los casos. La anatomía patológica mostró radicalidad en la primera cirugía en el 84,4% y supervivencia libre de enfermedad a los 10 años en el 84%. Conclusión: La técnica SNOLL es una técnica factible y precisa para la localización y tratamiento quirúrgico de microcalcificaciones malignas con supervivencia libre de enfermedad y porcentaje de recidiva comparable a otras técnicas. Asimismo, proponemos el afeitado sistemático de la cavidad para reducir la necesidad de reintervención.(AU)

Objectives: To evaluate the feasibility and accuracy of the ROLL technique to localize malignant mammary microcalcifications and the risk of local recurrence, we performed a multicentre prospective observational study to assess the application of the technique and progress of patients with a 10year follow-up. Materials and methods: Between 2007 and 2010, 64 patients were recruited. All the patients had been diagnosed with breast neoplasm due to microcalcifications on mammography and were treated with conservative surgery and sentinel lymph node biopsy. A technetium-99m injection was performed preoperatively, with a single or several punctures (> 3.5 cm lesions), guided by mammography or by ultrasound. In all cases, we performed a preoperative lymphoscintigraphy, to assess contrast migration, and intraoperative mammogram to assess correct removal of the lesion. Results: In the 64 patients, contrast injection could be confirmed, and lymphoscintigraphy proved correct migration of the contrast to the sentinel node, allowing excision of the mammary lesion and of the sentinel lymph node in 100%. The intraoperative mammogram showed complete lesion excision in 100% cases. The pathology showed radicality in the first surgery of 84.4% and showed a disease-free survival of 84% at 10 years. Conclusión: The SNOLL technique (ROLL + SNB) is a feasible and accurate technique for the localization and surgical treatment of malignant microcalcifications with disease-free survival and a relapse rate comparable to the rest of the techniques. Likewise, we propose systematic cavity shave to reduce the need for reinterventions.(AU)

Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study

Background Sequential treatment of Panitumumab (Pb) plus Paclitaxel (Px) as induction treatment (IT) followed by concurrent bioradiotherapy (Bio–RT) with Pb may be an alternative for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) in patients ineligible for high-dose cisplatin therapy. Methods Phase II, single-arm, multicentre study, with two-stage design, in patients ≥ 18 years with stage III–IVa–b LA-SCCHN unfit for platinum. Patients received Px + Pb (9 weeks) as IT followed by Bio–RT + Pb. Primary endpoint: overall response rate (ORR) after IT, defined as: more than 70% of patients achieving complete response (CR) or partial response (PR) to IT. Secondary end-points: progression-free survival, organ preservation rate, safety profile. Results Study ended prematurely (51 patients) due to slow recruitment. ORR: 66.7% (95% CI: 53.7–79.6), 8 (15.7%) CR and 26 (51.0%) PR. 39 patients (76%) completed radiotherapy (RT). Pb and/or Px-related adverse events (AEs) grade 3–4: 56.9% during IT and 63.4% during the concomitant phase, of which most common were skin toxicity (33.3%). Five deaths occurred during treatment, two of them (3.9%) were Pb and/or Px-related. Conclusions Although underpowered, ORR was higher than the pre-specified boundary for considering the treatment active. Although Px + Pb as IT provides some benefit, the safety profile is worse than expected. To consider Pb + Px as IT as an alternative for platinum-unsuitable LA-SCCHN, further research/investigation would be needed (AU)

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

BACKGROUND: The aim of this phase II study was to determine toxicity, response rate, time to progression, and overall survival of cisplatin, etoposide and gemcitabine in patients with carcinoma of unknown primary tumour site. PATIENTS AND METHODS: Thirty patients with no previous chemotherapy and not belonging to a treatable group were treated with cisplatin 70 mg/m(2) on day 1, etoposide 70 mg/m(2) on days 1 and 2, and gemcitabine 700 mg m(2) on days 1 and 8, administered every 3 weeks. Stable or responding patients received a maximum of eight cycles. Twenty patients (67%) had more than three affected sites, and 25 patients (84%) had adenocarcinomas. RESULTS: Overall response rate was 36.6% (11 patients), including four complete responses (13.3%) and seven partial responses (23.3%), with a 95% confidence interval of 19.9-56. Median survival was 7.21 months and eight patients remained alive for >1 year. Myelosuppression was the most important toxicity, with grade 3-4 neutropenia in 18 patients (60%) in 32% of the cycles: eight patients had neutropenic fever and 10 patients had thrombopenia in 11% of cycles. No non-haematological grade 4 toxicity occurred. CONCLUSIONS: Cisplatin, etoposide and gemcitabine is an active combination, inducing objective responses in a subset of heavily advanced disease patients with carcinoma of unknown primary site. The role of adding gemcitabine to cisplatin and etoposide remains to be resolved as to the best schedule to diminish toxicity for the three-drug combination.

Cáncer oculto de la mama. Caso clínico y revisión de la literatura / Occult breast cancer. Case report and literature review

Se presenta el caso clínico de una paciente con un cáncer oculto de la mama. La situación clínica en la que se detectan ganglios axilares afectos por metástasis de adenocarcinoma pero sin evidenciarse tumor en la mama no es frecuente: entre el 0,3 y 0,8% de todos los tumores de la mama. En esta revisión se subraya la importancia que está adquiriendo el PET como técnica de elección en la detección del tumor primario así como en la monitorización de la respuesta a la quimioterapia neoadyuvante. Asimismo, se repasan los diferentes y controvertidos tratamientos propuestos. La tendencia actual es de máxima conservación, preconizando la disección axilar con radioterapia y tratamiento sistémico posteriores. En este último adquiere especial importancia el análisis inmunohistoquímico de la metástasis ganglionar para un diseño adecuado de la quimioterapia y los agentes anti-diana (AU)

We report the case of a patient with occult cancer of the breast. A finding of metastatic adenocarcinoma to the axillary nodes with no apparent mass in the breast is rare, occurring in 0.3% to 0.8% of all breast tumors. This review of the literature highlights the importance of positron emission tomography, which is becoming the gold standard in the detection of primary tumors and in monitoring response to neoadjuvant chemotherapy. The various treatments proposed and their controversies are also discussed. The current trend is breast conservation. Axillary dissection, adjuvant radiotherapy and systemic treatment are recommended. In the latter, immunohistochemical analysis of lymph node metastases is particularly important for the appropriate design of chemotherapy and anti-target agents (AU)

Monitorización de la respuesta a la terapia neoadyuvante en el carcinoma de mama localmente avanzado mediante métodos de imagen / No disponible

Objetivo: Establecer la validez diagnóstica de la mamografía, de la resonancia magnética y de la gammagrafía 99mTc-sestamibi en la valoración de la respuesta terapéutica de pacientes diagnosticadas de carcinoma de mama localmente avanzado. Pacientes y métodos: Estudio prospectivo observacional aprobado por el Comité Ético de nuestra institución en el que se han incluido 75 pacientes diagnosticadas de carcinoma de mama localmente avanzado por core biopsia (edad media: 52 años, rango: 26-80 años). Las pacientes fueron valoradas clínicamente, por mamografía, resonancia magnética y gammagrafía 99mTc-sestamibi antes de iniciar la terapia neoadyuvante y una vez finalizada la misma. Se han administrado regímenes terapéuticos basados en antraciclinas excepto en siete pacientes que recibieron hormonoterapia con inhibidores de la aromatasa. Para la valoración de la respuesta clínica se utilizaron los criterios RECIST y los mismos criterios, adaptados y consensuados, se emplearon para la valoración de la respuesta mediante técnicas de imagen e histología. Resultados: Tras cirugía se constató respuesta histológica, bien sea parcial o completa, en 61 pacientes (81,3%). Se evidenció conformidad entre la respuesta clínica y los hallazgos histológicos en el 80% de los casos, entre mamografía e histología en el 79,7% de casos, y esta fue del 78,9 % para la resonancia magnética y del 86,4% para la gammagrafía. La sensibilidad y especificidad fueron del 64,3 y del 83,8% para la mamografía, del 61,5 y 82,8% para la resonancia magnética, y del 58,3 y 92,6%, para la gammagrafía. Se pudo observar una concordancia del 88,8% entre resonancia y gammagrafía, del 75,7% entre esta y la mamografía y del 77,3 % entre gammagrafía y mamografía. Conclusiones: La resonancia magnética y la gammagrafía 99mTc-sestamibi demuestran su utilidad en la valoración de la respuesta tras la terapia neoadyuvante, si bien persiste la dificultad en la valoración de focos microscópicos de tumor o del componente in situ, y por tanto, en la definición de respuesta completa(AU)

Aim: To establish diagnostic validity of mammography, mammary magnetic resonance and 99mTc-sestamibi scintimammography to assess response to neoadjuvant therapy in patients with locally advanced breast cancer. Patients and methods: A prospective observational study was approved at our institution which included 75 women with core biopsy diagnostic of locally advanced breast cancer (mean age: 52 y, range 26-80 y). All patients had clinical, mammography, mammary magnetic resonance and 99mTc-sestamibi scintimammography assessment before and after receiving neoadjuvant therapy. Primary chemotherapy based on anthracyclines was administered except in seven patients who received endocrine therapy with aromatase inhibitors. RECIST criteria were considered for clinical response assessment, and the same criteria were adapted for imaging methods and pathologic response. Results: After surgery, 61 patients (81,3%) showed histologic response (complete or partial). Clinical assessment of tumour response was in concordance with histologic study in 80% of patients. Mammography, magnetic resonance and scintimammography agreed with pathology in 79,7, 78,9 and 86,4% of patients, respectively. Based on histologic response, sensitivity and specificity were 64,3 and 83,8% for mammography, 61,5 and 82,8% for magnetic resonance, and 58,3 and 92,6% for scintimammography, respectively. Agreement between magnetic resonance and scintimammography was 88,8%, between magnetic resonance and mammography 75,7%, and 77,3% between scintimammography and mammography. Conclusion: Magnetic resonance and scintimammography should be added to the diagnostic arsenal since they have shown more reliability than conventional methods for predicting histopathologic response to neoadjuvant therapy. Nevertheless, tumour size is critical for the detection of residual small lesions, usually microscopic and DCIS foci, or in others words, there is a limitation to define complete response(AU)

Intensidad de dosis recibida en el tratamiento quimioterápico del cáncer de mama / No disponible

Objetivo: Conocer las intensidades de dosis relativas (IDR) enpacientes con cáncer de mama y tratamiento quimioterápico.Determinar el número de pacientes donde la IDR fue < 85% de laprogramada y posible causa.Método: Estudio retrospectivo, periodo de selección de 4 meses.Se registraron: edad, superficie corporal, protocolo administrado,intención de tratamiento, frecuencia de administración de ciclos,número de tratamientos citostáticos recibidos anteriormente y administraciónde filgrastim. Se calculó la IDR media por paciente y protocolo.Resultados: Se analizaron 110 pacientes, edad media 55,4años (intervalo: 31-84), superficie corporal media 1,7 m2 (1,3-2,4). La IDR media global fue 91,0% (DE 10,7). Del 93,8%(10,6), 95,8% (6,3) y 81,9% (18,5) en neoadyuvancia, adyuvanciay tratamiento paliativo, respectivamente. El 20% de pacientesno alcanzó una IDR >= 85% de la programada, IDR media 69,5%(3,29). Un retraso en la administración de quimioterapia igual osuperior a 7 días ocurrió en un 45,4% de los casos, IDR media80,7% (16,0). En los episodios donde se disminuyó la dosis portoxicidad la IDR media fue 75,6% (13,6). Se obtuvieron relacionesinversas significativas de la edad (p = 0,02) y línea de tratamiento(p = 0,03) con la IDR. En un 36,8% la reducción de dosisfue por neutropenia, recibiendo filgrastim el 52,9%.Conclusiones: La mayoría de pacientes recibió una IDR adecuada.La edad, tratamientos anteriores e intención de tratamientofueron las variables que más afectaron a la dosis recibida. Elretraso en la administración del ciclo fue la actuación más frecuentepara minimizar la toxicidad y que menos afectó al tratamiento

Objective: To know relative dose intensity (RDI) in patientswith breast cancer treated with chemotherapy. To determine thenumber of patients where RDI was < 85% of that programmedand the possible cause.Method: Retrospective study, four-month selection period.The following were recorded: age, body surface, protocol applied,intention of treatment, frequency of administration of cycles,number of cytostatic treatments previously received and filgrastimadministration. The average RDI per patient and protocol was calculated.Results: 110 patients were analysed, the average age of thembeing 55.4 years (interval: 31-84), average body surface 1.7 m2(1.3-2.4). Overall average RDI was 91.0% (SD 10.7). 93.8%(10.6), 95.8% (6.3) and 81.9% (18.5) in neoadjuvant, adjuvantand palliative treatments, respectively. 20% of the patients did notreach a RDI >= 85% of that programmed, average RDI 69.5%(3.29). A delay in the administration of chemotherapy equal orgreater than seven days occurred in 45.4% of the cases, averageRDI 80.7% (16.0). In the episodes where the dose was reducedbecause of toxicity, the RDI was 75.6% (13.6). Significant inverseratios were obtained with age (p = 0.02) and line of treatment(p = 0.03) with the RDI. In 36.8%, dose reduction was caused byneutropenia; 52.9% received filgrastim.Conclusions: Most patients received the appropriate RDI.Age, previous treatments and intention of treatment were thevariables with the greatest impact on the dose received. The delayin administering the cycle was the most frequent act minimisingthe toxicity and which least affected the treatment